Devendra K Hiwase

List of Publications by Year in Descending Order

57 papers	616 citations	12 h-index	24 g-index
64 ext. papers	830 ext. citations	3.6 avg, IF	3.43 L-index

#	Paper	IF	Citations
57	A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia. *Blood*, **2021**, 138, 1261-1261	2.2	0
56	A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes. *Blood*, **2021**, 138, 3675-3675	2.2	0
55	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. *Blood*, **2021**, 138, 368-368	2.2	0
54	Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS. *Blood*, **2021**, 138, 1532-1532	2.2	0
53	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. *Blood*, **2021**, 138, 3377-3377	2.2	
52	Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups. *Blood*, **2021**, 138, 3702-3702	2.2	1
51	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. *Blood*, **2021**, 138, 2351-2351	2.2	0
50	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. *Leukemia*, **2021**, 35, 3245-3256	10.7	10
49	Outcomes and health care utilization of older patients with acute myeloid leukemia. *Journal of Geriatric Oncology*, **2021**, 12, 243-249	3.6	1
48	Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. *Journal of Hematology and Oncology*, **2021**, 14, 133	22.4	2
47	Childhood acute myeloid leukemia shows a high level of germline predisposition. *Blood*, **2021**, 138, 2293-2298	2.2	0
46	Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. *Blood Advances*, **2021**, 5, 5107-5111	7.8	2
45	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. *Blood Advances*, **2020**, 4, 1131-1144	7.8	37
44	Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes. *Blood*, **2020**, 136, 34-35	2.2	
43	Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial. *Blood*, **2020**, 136, 22-23	2.2	1
42	Clinical Effectiveness of Conjugate Pneumococcal Vaccination in Hematopoietic Stem Cell Transplantation Recipients. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 421-427	4.7	7
41	Genomics of therapy-related myeloid neoplasms. *Haematologica*, **2020**, 105, e98-e101	6.6	10

40	Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 782-788	4.7	6
39	The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. *Transfusion*, **2020**, 60, 2192-2198	2.9	3
38	Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes. *Journal of Geriatric Oncology*, **2020**, 11, 128-130	3.6	2
37	Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. *Journal of Geriatric Oncology*, **2020**, 11, 114-120	3.6	16
36	Correct application of variant classification guidelines in germline mutated disorders to assist clinical diagnosis. *Leukemia and Lymphoma*, **2020**, 61, 246-247	1.9	2
35	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. *Leukemia*, **2019**, 33, 2842-2853	10.7	19
34	Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. *Blood*, **2019**, 134, 85-89	2.2	14
33	Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance. *Haematologica*, **2019**, 104, e451-e454	6.6	6
32	Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. *Blood Advances*, **2019**, 3, 370-374	7.8	2
31	Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. *HemaSphere*, **2019**, 3, e314	0.3	11
30	Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study. *HemaSphere*, **2019**, 3, e224	0.3	4
29	Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. *Haematologica*, **2019**, 104, 700-709	6.6	5
28	Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. *Internal Medicine Journal*, **2019**, 49, 152-159	1.6	7
27	Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. *Leukemia Research*, **2018**, 67, 109-115	2.7	8
26	Success is built on failures: tackling the challenge of ponatinib failure. *Leukemia and Lymphoma*, **2018**, 59, 1279-1281	1.9	1
25	Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. *Blood*, **2018**, 132, 3101-3101	2.2	2
24	A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML. *HemaSphere*, **2018**, 2, e158	0.3	2
23	Inflammatory myopathies after allogeneic stem cell transplantation. *Muscle and Nerve*, **2018**, 58, 790-795	3.4	15

22	Myeloid neoplasms with germline DDX41 mutation. *International Journal of Hematology*, **2017**, 106, 163-174	1.9	44
21	Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. *American Journal of Hematology*, **2017**, 92, 508-514	7.1	16
20	The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. *Leukemia Research*, **2017**, 57, 102-103	2.7	
19	Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. *Haematologica*, **2017**, 102, 2021-2029	6.6	28
18	Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA).. *Journal of Clinical Oncology*, **2017**, 35, 7056-7056	2.2	1
17	Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations. *Blood*, **2016**, 128, 1212-1212	2.2	2
16	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 2011-2011	2.2	3
15	Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study. *Blood*, **2016**, 128, 5447-5447	2.2	
14	High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?. *Blood*, **2016**, 128, 3989-3989	2.2	
13	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. *Blood*, **2015**, 125, 915-23	2.2	65
12	Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. *Blood*, **2015**, 126, 1644-1644	2.2	1
11	Prevalence of Cardiac and Hepatic Siderosis in Australian Patients with Transfusion-Dependent Anemias or Non-Transfusion-Dependent Thalassemia, As Assessed By MRI (the TIMES study). *Blood*, **2015**, 126, 540-540	2.2	
10	RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. *Blood*, **2015**, 126, 3562-3562	2.2	
9	Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. *Haematologica*, **2013**, 98, 896-900	6.6	11
8	Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. *Blood*, **2013**, 122, 1503-1503	2.2	13
7	Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients. *Blood*, **2013**, 122, 1518-1518	2.2	2
6	STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner. *Blood*, **2013**, 122, 2705-2705	2.2	
5	Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Leukemia and Lymphoma*, **2012**, 53, 1251-2	1.9	2

4	Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. *Expert Review of Hematology*, **2011**, 4, 285-99	2.8	5
3	Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 116-24	4.7	66
2	Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. *Clinical Cancer Research*, **2008**, 14, 3881-8	12.9	157
1	Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia281-295		